Post by
24minus7 on Jul 14, 2023 4:59am
Future of TFC-039
By Trenibrother@w:o:
Just over six months ago, Sirona signed an expanded, international partnership agreement with Wanbang to work together.
"The agreement expands the partnership to include human health due to new licensing opportunities that are currently in due diligence," he said.
"Wanbang (a wholly owned subsidiary of Shanghai Fosun Pharmaceutical) and Sirona initially signed a licensing agreement for TFC-039, with Wanbang obtaining the rights to develop the compound for the treatment of diabetes in China and Sirona retaining the worldwide rights."
This clearly clarifies the relationships over intellectual property.
"Recently, Sirona completed due diligence with a large pharmaceutical company with regional interest in developing the compound for diabetes in humans."
"The shared data spans more than 12 years of research and development and includes in vitro and in vivo preclinical work, multiple clinical trials, development of advanced manufacturing processes and the ability to commercially manufacture TFC-039."
https://www.sironabiochem.com/sirona-biochem-signs-internati...
There has been interest from several partners in Animal Health for years. What would be the point of entering into a partnership agreement not so long ago with Wanbang knowing the partner could jeopardise potential licensing agreements due to completely excessive demands or withholding needed data material?
Regardless, a large pharmaceutical company has regional interest in the compound for use in human medicine. Regional could mean North America, Europe or anything but China.
In principle, no interested party needs Wanbang's data material, because a large pharmaceutical company conducts independent due diligence, which includes its own clinical studies. Of course, it would be an advantage to have access to existing data material, but it is not absolutely necessary. Thus, Wanbang plays no role at all, if only because of the regional interest.
The only striking thing about yesterday's update is that Sirona has always differentiated between animal health and human medicine in its communication up to now, but this time it has only referred to TFC-039 in very general terms.